Understanding Tysabri-Related PML: Diagnosis, Monitoring, and Prognosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specific Pharmaceutical Risk

If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding how doctors evaluate this rare brain infection is critical. The medical community has long relied on post-market surveillance to assess the safety of biologic therapies, and this page explains the diagnostic process, monitoring protocols, and what the long-term outlook may entail.

Tysabri and PML: A Bridge from General Risk to Specific Harm

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, highlighting this risk and requiring that the drug be prescribed only through the restricted TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is typically confirmed through brain imaging, cerebrospinal fluid analysis for JCV DNA, and, if necessary, brain biopsy. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This immunosuppressive effect in the central nervous system allows latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA-approved labeling requires that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication of the disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program mandates that patients be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these monitoring requirements, PML can still occur, and the timeline between exposure and documented harm can range from a few months to several years, as seen with other serious infections associated with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in California

For patients in California who have developed PML after Tysabri treatment, settlement-related considerations are complex. The adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning and TOUCH program are designed to inform patients and healthcare providers of the risk, but questions may arise about whether these warnings were sufficient to allow patients to make fully informed decisions. In California, the statute of limitations for personal injury claims, including those related to pharmaceutical products, generally requires that a lawsuit be filed within two years from the date the injury was discovered or should have been discovered. For PML, the date of discovery may be the date of diagnosis, but this can be complicated by the insidious onset of symptoms and the need for confirmatory testing. Patients who were diagnosed with PML after Tysabri exposure should consult with legal counsel to determine the applicable deadlines for their specific case. Settlement considerations for affected patients may include compensation for medical expenses, lost wages, pain and suffering, and other damages. The timeline between Tysabri exposure and the development of PML is critical for establishing causation. Patients who received Tysabri for longer durations, especially beyond two years, and who had anti-JCV antibodies or prior immunosuppressant use, are at higher risk and may have stronger claims. However, each case must be evaluated individually based on the patient's medical history, treatment duration, and the specific circumstances of their PML diagnosis. In summary, Tysabri-associated PML is a severe and often fatal condition with well-defined risk factors and a mandated monitoring program. Patients in California who have been harmed should be aware of the statute of limitations and seek legal advice promptly. The adequacy of warnings and the timeline of exposure are key factors in any potential settlement or litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Tysabri, generally requires that a lawsuit be filed within two years from the date the injury was discovered or should have been discovered. For PML, the date of discovery may be the date of diagnosis, but due to the insidious onset of symptoms, it is important to consult with legal counsel to determine the applicable deadline for your specific case.

What are the risk factors for developing PML from Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with these risk factors should be closely monitored for any signs of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.